NHLBI TRANS-OMICS FOR PRECISION MEDICINE (TOPMED) FOR THE CENTRALIZED OMICS RESOURCE (CORE) - RNA-SEQ

NHLBI的Trans-Omics for Precision Medicine(TOPMed)计划始于2014年，是支持心、肺、血液疾病和睡眠障碍的精准药物开发的旗舰计划。主要目标是产生大量的基因组数据，这些数据具有足够的统计能力来进行科学发现。数据首先在TOPMed中生成和处理，然后上传到外部数据库、基因型和表型数据库(DBGaP)和BioData Catalyst(BDC)供研究人员访问。2016年，根据TOPMed计划，NHLBI资助了九(9)个集中式Omics资源(CORE)中心，这些中心产生了大约200,000个全基因组测序和多组学数据。随着TOPMed进入专注于功能基因组学和疾病机制的下一阶段TOPMed2.0，核心需要升级到核心2.0，以生成更多功能基因组数据，包括单细胞分辨率的组学数据。核心2.0需要生成大量的功能基因组数据，需要能够提供高能力生成组学数据的承包商。

NHLBI's Trans-Omics for Precision Medicine (TOPMed) program started in 2014 as the flagship program supporting the development of precision medicine for heart, lung, blood diseases and sleep disorders. The main goal is to generate a large volume of genomics data that have sufficient statistical power for scientific discovery. The data are generated and processed first in TOPMed before being uploaded to external databases, database of Genotypes and Phenotypes (dbGaP) and BioData Catalyst (BDC) for researchers to access. In 2016, under TOPMed program, NHLBI funded nine (9) Centralized Omics Resource (CORE) centers that have generated approximately 200,000 whole genome sequencing and multi-omics data. As TOPMed enters its next phase TOPMed2.0 focusing on functional genomics and disease mechanism, the CORE needs to be upgraded to CORE 2.0 generating more functional genomics data, including omics data at single-cell resolution. CORE 2.0 needs to generate a large volume of functional genomics data and is in need of contractors that can provide a high capability of generating omics data.